Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
182 hedge funds and large institutions have $1.47B invested in Provention Bio, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 52 increasing their positions, 35 reducing their positions, and 27 closing their positions.
800% more funds holding in top 10
Funds holding in top 10: 1 → 9 (+8)
208% more capital invested
Capital invested by funds: $477M → $1.47B (+$992M)
181% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 27
68% more call options, than puts
Call options by funds: $45.6M | Put options by funds: $27.1M
49% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 35
37% more funds holding
Funds holding: 133 → 182 (+49)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$39.3M |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$36.7M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$18.6M |
| 4 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$17.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sessa Capital
New York
|
-$75.3M |
| 2 |
VA
VR Adviser
New York
|
-$11.8M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$8.87M |
| 4 |
D.E. Shaw & Co
New York
|
-$8.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$6.2M |
PRVB Hedge Fund Activity: Q1 2023 in Review
182 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q1 2023, worth a combined $1.47B — up 208% from $477M a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new PRVB positions and 27 closed out — a net gain of 49 holders — while 52 added to existing stakes and 35 trimmed.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $39.3M. The largest seller was Sessa Capital, cutting an estimated $75.3M.
- 182 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q1 2023, up from 133 in Q4 2022.
- Funds reported $1.47B of Provention Bio, Inc. Common Stock stock for Q1 2023, up 208% quarter-over-quarter.
- 76 funds opened new Provention Bio, Inc. Common Stock positions in Q1 2023 and 27 closed out, a net change of +49 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q1 2023 was Pentwater Capital Management, an estimated $39.3M added.
- The largest Provention Bio, Inc. Common Stock seller in Q1 2023 was Sessa Capital, an estimated $75.3M sold.
Based on aggregated 13F filings for Q1 2023.